Psoriatic Arthritis - A Pipeline Analysis Report | Technavio
LONDON--(BUSINESS WIRE)--May 15, 2018-- has announced their latest pipeline analysis report on the . The report comprises an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat psoriatic arthritis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180515005779/en/
Technavio has published a new pipeline analysis report on the global psoriatic arthritis market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Psoriatic Arthritis - market overview
Psoriatic arthritis is an interminable joint pain leading to inflammation in people suffering from psoriasis, a type of skin disorder. Psoriasis can lead to scaly red and white skin patches. Psoriatic arthritis is commonly observed in large joints, especially those of the lower extremities, distal joints of the fingers and toes, and can affect the back and sacroiliac joints of the pelvis. It is mostly observed in individuals between the age group of 30 and 50, however, it can start at early ages too.
According to a senior analyst at Technavio for research , “Youngsters suffering from psoriatic arthritis are additionally in danger of developing uveitis, which is swelling of the middle layer of the eye. Around 15% of people with psoriasis can develop psoriatic joint inflammation. On rare occasions, the joint inflammation can show up before the skin issue.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Psoriatic arthritis – market segmentation
This market research report segments the based on therapies employed (monotherapy and unknown), therapeutic modalities (monoclonal antibody, small molecule and recombinant fusion proteins), and RoA (subcutaneous, IV, oral, and undisclosed).
The subcutaneous RoA is expected to account for around 38% of the market share followed by the oral and IV segments. In terms of therapeutic modalities, the monoclonal antibody segment accounted for 69% of the market share, followed by the small molecule segment.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180515005779/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/15/2018 07:14 AM/DISC: 05/15/2018 07:13 AM